Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography.

Yu GP, Na R, Ye DW, Qi J, Liu F, Chen HT, Wu YS, Zhang GM, Sun JL, Zhu Y, Huang LQ, Ren SC, Jiang DK, Zheng SL, Jiang HW, Sun YH, Ding Q, Xu J.

Asian J Androl. 2016 Jul-Aug;18(4):633-8. doi: 10.4103/1008-682X.172823.

2.

Glycosylation status of serum immunoglobulin G in patients with prostate diseases.

Kazuno S, Furukawa J, Shinohara Y, Murayama K, Fujime M, Ueno T, Fujimura T.

Cancer Med. 2016 Jun;5(6):1137-46. doi: 10.1002/cam4.662. Epub 2016 Feb 16.

3.

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia.

Kitagawa Y, Namiki M.

Asian J Androl. 2015 May-Jun;17(3):475-80. doi: 10.4103/1008-682X.143756. Review.

4.

Day care monopolar transurethral resection of prostate: Is it feasible?

Khan A.

Urol Ann. 2014 Oct;6(4):334-9. doi: 10.4103/0974-7796.140998.

5.

Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.

Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C.

Prostate Int. 2014 Sep;2(3):133-9. doi: 10.12954/PI.14054. Epub 2014 Jul 30.

6.

Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer.

Murray NP, Reyes E, Fuentealba C, Orellana N, Jacob O.

J Oncol. 2014;2014:612674. doi: 10.1155/2014/612674. Epub 2014 Aug 19.

7.
8.

The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis.

Jie C, Rongbo L, Ping T.

Eur Radiol. 2014 Aug;24(8):1929-41. doi: 10.1007/s00330-014-3201-2. Epub 2014 May 28. Review.

9.

The effects of cigarette smoking on prostate-specific antigen in two different age groups.

Koc G, Akgul K, Yilmaz Y, Dirik A, Un S.

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E704-7. doi: 10.5489/cuaj.358.

10.

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

J Urol. 2011 May;185(5):1650-5. doi: 10.1016/j.juro.2010.12.032. Epub 2011 Mar 17. Erratum in: J Urol. 2011 Jul;186(1):354.

11.

Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.

Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, Catalona WJ.

Urology. 2010 Nov;76(5):1072-6. doi: 10.1016/j.urology.2009.11.056. Epub 2010 Sep 16.

12.

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL.

Arch Intern Med. 2010 Jul 26;170(14):1256-61. doi: 10.1001/archinternmed.2010.221.

13.

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Ulmert D, O'Brien MF, Bjartell AS, Lilja H.

Nat Rev Urol. 2009 Jul;6(7):384-91. doi: 10.1038/nrurol.2009.123. Review.

14.

Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.

Berglund RK, Stephenson AJ, Cronin AM, Vickers AJ, Eastham JA, Klein EA, Guillonneau BD.

Urology. 2009 May;73(5):1098-103. doi: 10.1016/j.urology.2008.07.052. Epub 2009 Mar 17.

15.

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.

Määttänen L, Hakama M, Tammela TL, Ruutu M, Ala-Opas M, Juusela H, Martikainen P, Stenman UH, Auvinen A.

Br J Cancer. 2007 Jan 15;96(1):56-60.

16.
17.

Supplemental Content

Support Center